HERALD TR study

TR study of "A basket trial of DS-8201a, a novel HER2-targeted antibody-drug conjugate, for HER2 amplified solid tumors identified by ctDNA analysis"

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080224684

Enrollment

Registered

2019-05-16

Start date

2019-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid malignancies

Interventions

investigational material(s) Generic name etc : DS-8201a INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Enrolled in HERALD trial. 2.Informed consent for participation in the HERALD TR study is obtained at the discretion of the patient.

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
exploratory Analysis of cancer-related genetic abnormalities Analysis of Protein expression Analysis of mRNA and cfRNA expression Analysis of circulating tumor cells	—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Contacts

Public Contactclinical trial coordinating committee

National Cancer Center Hospital East

HERALD_core@east.ncc.go.jp+81-4-7133-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026